Thyroid Cancer | Tumor

CURE’s thyroid cancer page is an extensive resource of cancer information featuring the latest thyroid cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on thyroid cancer.

Oncology Drugs Approved by the FDA in September 2024

October 1st 2024, 3:00pm

Article

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

FDA Approves Retevmo for Some With Medullary Thyroid Cancer

September 27th 2024, 7:48pm

Article

The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer.

Study Confirms Lenvima’s Benefits in Thyroid Cancer

September 19th 2024, 9:00pm

Article

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

Managing Quality of Life After Iodine Treatment for Thyroid Cancer

August 7th 2024, 3:00pm

Video

Interventions, such as speech therapy, after receiving radioactive iodine treatment for thyroid cancer may help manage quality of life.

FDA Approvals for Solid Cancers in June

July 1st 2024, 7:00pm

Article

The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.

Retevmo Approval the Beginning of Targeted Therapy for RET-Mutant Childhood Cancer

June 25th 2024, 3:00pm

Article

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population.

FDA Approves Retevmo for Some Adults and Children With Thyroid Cancer

June 12th 2024, 7:00pm

Article

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

FDA Approves Retevmo for RET-Positive Pediatric Cancers

May 29th 2024, 4:41pm

Article

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Retevmo Improves RET-Mutant Thyroid Cancer Outcomes

August 25th 2023, 1:00pm

Article

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer.

Addressing Unmet Needs in Differentiated Thyroid Cancer

May 12th 2022, 1:00pm

Video

Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.